Curative Biotechnology Inc
OTC:CUBT
Operating Margin
Curative Biotechnology Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
C
|
Curative Biotechnology Inc
OTC:CUBT
|
9.2m USD | N/A | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
633.6T EUR | N/A | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
144.7B USD |
3%
|
|
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
92.2B USD |
10%
|
|
| IN |
S
|
SAB Industries Ltd
BSE:539112
|
2.3B INR |
11%
|
|
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
82.6B Zac |
62%
|
|
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
69.6B USD |
10%
|
|
| US |
|
Coupang Inc
F:788
|
46B EUR |
2%
|
|
| US |
C
|
Circle Internet Group Inc
NYSE:CRCL
|
46.2B USD |
10%
|
|
| ID |
|
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
616.4T IDR |
41%
|
|
| CH |
G
|
Galderma Group AG
SIX:GALD
|
28.8B CHF |
15%
|
Curative Biotechnology Inc
Glance View
Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. The company is headquartered in Boca Raton, Florida. The company went IPO on 2001-07-11. The firm is focused on identifying, acquiring and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech has ongoing programs in three different therapeutic areas: infectious disease, neuro oncology and degenerative eye disease. The firm's pipeline includes IMT504, CURB906 and Metformin Reformulation. IMT504 is a immune therapy to treat rabies. CURB906 is a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. Metformin Reformulation to treat degenerative eye disease.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Curative Biotechnology Inc's most recent financial statements, the company has Operating Margin of 0%.
You don't have any saved screeners yet